Study of Semaglutide, and Cilofexor/Firsocostat, Alone and in Combination, in Adults With Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) (WAYFIND)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT04971785

Recruitment Status : Active, not recruiting

First Posted : July 21, 2021

Last Update Posted : February 28, 2024

View this study on the modernized ClinicalTrials.gov

Sponsor:

Collaborator:

Novo Nordisk A/S

Information provided by (Responsible Party):

Gilead Sciences

Study Details
Tabular View
No Results Posted
Disclaimer
How to Read a Study Record

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Active, not recruiting
Estimated Primary Completion Date :	November 2024
Estimated Study Completion Date :	December 2024

To Top